Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant

Hematological Malignancies Clinical Trial

Official title:

An Observational Retrospective/Prospective Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant Using Peripheral Blood Stem Cells (PBSC) From Unrelated or Related, HLA-identical or Partially Mismatched Donors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02300571
• Other study ID #: HDCTX 2013
• Status: Recruiting
• Phase: N/A
• First received: November 21, 2014
• Last updated: September 1, 2017
• Start date: September 2013
• Est. completion date: January 2018

Study information

• Verified date: August 2017
• Source: Fondazione del Piemonte per l'Oncologia
• Contact: Fabrizio Carnevale-Schianca, MD
• Phone: +39011993
• Email: fabrizio.carnevale[@]ircc.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational study is proposed to observe the effect of high-dose, post-transplantation cyclophosphamide after a T cell-replete, HLA-matched PBSC graft from an HLA-identical or mismatched donor.

Description:

Allogeneic hematopoietic cell transplantation (HCT) remains the only curative approach for many hematological malignancies. In allogeneic HCT the donor immune system through the donor lymphocytes exerts both a beneficial and detrimental effect. Graft versus host disease (GVHD) represents the major complication and cause of mortality of allogeneic HCT. The principal aim that clinical transplant research must accomplish in the next years is to elaborate a transplant strategy devoid of any GVHD but still capable of generating, through donor lymphocytes, the graft versus tumor effect (GVT). The most used GVHD prophylaxis regimen remains the association of a calcineurin-inhibitor (CNIs) for six months and four low-doses of methotrexate (MTX) but the long length prophylaxis impacts on the process of post-transplant immune reconstitution slowing it down and exposing patients to a high risk of developing severe infections. The use of post-transplant cyclophosphamide looks the most promising among the new approaches to GVHD control. The study design is an observational retrospective/prospective Study in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant using Peripheral Blood Stem Cells (PBSC) from unrelated or related, HLA-identical or partially mismatched donors. In case of unrelated donor, donor selection will be done accordingly to Italian Bone Marrow Donor Registry (IBMDR). This protocol and the treatment plan outlined below are limited to the plan or GVHD prevention.

The treatment plan for all patients including pre-conditioning therapy, TBI/chemotherapy, central nervous system prophylaxis and other planned therapies, is described in the primary transplant protocols which the patient has been assigned by the investigational site.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patient is scheduled for transplant of 'mobilized' peripheral blood stem cells (PBSC) from a genotypically HLA-unrelated or related identical or partially mismatched stem cell donor.

2. Patient is = 18 years and = 65 years of age.

3. Diagnosis of malignancy. Patients will be divided on the basis of their disease in low risk and high risk patients.

High risk diseases: AML > CR1, ALL > CR1, CML in CP #2, AP or BP, non-Hodgkin's lymphoma > CR2, Hodgkin's lymphoma > CR2, other patient with refractory malignancy Low risk: multiple myeloma (all patients), AML in CR1, myelodysplastic syndrome beyond RA (including CMML) and ALL in CR1.

4. Patient or legal guardian has signed/dated the informed consent form.

5. Female patients must have a negative pregnancy test (blood or urine) unless they are prepuberal or surgically sterile.

6. Estimated Creatinine Clearance = 60 mL/min at time of consent.

7. Total bilirubin is = 1.5 times the upper limit of normal at time of consent.

8. SGOT and SGPT are = 2.0 times the upper limit of normal at time of consent.

Exclusion Criteria:

1. Patient > 65 years of age

2. Patient has not signed/dated the informed consent form.

3. Patient is receiving a T-cell depleted hematopoietic stem cell graft.

4. Pregnant or lactating women

5. Patient has an acute pulmonary infection suspected on the basis of abnormal chest x-ray.

6. Patient has an active systemic infection not controlled with anti-microbial therapy.

7. Patient is a known carrier of any of the Human Immune Deficiency Viruses (HIV-1 or others).

Related Conditions & MeSH terms

• Graft vs Host Disease
• Hematological Malignancies

Locations

Country	Name	City	State
Italy	Fondazione del Piemonte per l'Oncologia	Candiolo
Italy	Ospedale Regina Margherita	Torino

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione del Piemonte per l'Oncologia

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of the observed GVHD rate and infections	Evaluations through day 100 after transplantation will be performed with: Complete blood count (CBC), including differential and platelet count per standard practice guidelines at the performance site.; Blood chemistries: including sodium, potassium, chloride, bicarbonate (HCO3) or total carbon dioxide (CO2), glucose, blood urea nitrogen (BUN), creatinine, calcium, magnesium, phosphorus, total bilirubin, total protein, albumin, serum glutamic oxaloacetic transaminase (SGOT), lactic dehydrogenase (LDH), alkaline phosphatase per standard practice guidelines at the performance site.; Tacrolimus whole blood concentrations weekly starting on day 6. CMV surveillance, Aspergillus surveillance will be performed per standard practice guidelines at the performance site.; Evaluations after 100 days post-transplant will be completed per standard practice guidelines at each performance site.	100 day
Secondary	Overall survival	To determine the overall survival at 1 years (OS)	1 years
Secondary	Progression-free survival	To determine progression-free survival at 1 years (PFS)	1 years